Back to Journals » Drug Design, Development and Therapy » Volume 11

Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy

Authors D’Erme AM, Romanelli M, Chiricozzi A

Received 17 February 2017

Accepted for publication 20 April 2017

Published 15 May 2017 Volume 2017:11 Pages 1473—1480

DOI https://doi.org/10.2147/DDDT.S113192

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Rajendra Narayan Mitra

Peer reviewer comments 2

Editor who approved publication: Dr Tuo Deng

Angelo Massimiliano D’Erme,1,2 Marco Romanelli,2 Andrea Chiricozzi2

1Dermatology Unit, Livorno Hospital, Livorno, 2Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Abstract: Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The currently available therapeutics are limited, and AD management becomes challenging in most cases. Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor α subunit that is able to block the signaling of both IL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD. Dupilumab is ready to inaugurate a long and promising biological target treatment option for Th2 cell-mediated atopic immune response that characterizes AD.

Keywords: dupilumab, atopic dermatitis, eczema, IL-4, IL-13, biologics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]